Here Is What You Need To Know Before Investing In Immatics N.V. (IMTX)

Immatics N.V. (NASDAQ:IMTX) is among the 13 Best German Stocks to Invest in Now. On May 31, the company shared results from the ongoing Phase 1b clinical trial evaluating the efficacy of IMA203 PRAME cell therapy in heavily pretreated patients with metastatic melanoma.

Here Is What You Need To Know Before Investing In Immatics N.V. (IMTX)

A close-up of test tubes and laboratory equipment, showing the complexity of biopharmaceutical research.

The updated data showed that the treatment is well-tolerated and demonstrated durable responses with a confirmed ORR of 56%. Cedrik Britten, M.D., Chief Medical Officer at Immatics N.V. (NASDAQ:IMTX), stated the following on the development:

“Patients with advanced melanoma post-failure of checkpoint inhibition are left to face frequent and often rapid disease progression and limited long-term survival. These individuals are in urgent need of new treatments that deliver deeper and more durable responses. We believe the data presented today emphasize the strength, durability and tangible therapeutic potential of our one-time infusion PRAME cell therapy, IMA203, in this patient population. These positive results reinforce our commitment to actively advance IMA203 through the ongoing Phase 3 SUPRAME trial to bring this PRAME therapy to the market as soon as possible.”

Immatics N.V. (NASDAQ:IMTX) focuses on the research and development of potential T cell redirecting immunotherapies for cancer treatment. While the stock is down nearly 20% year-to-date, Wall Street analysts have a one-year average price target of $14.33 per share, reflecting a 151% upside potential from its current trading level.

On May 28, Deutsche Bank initiated coverage of Immatics N.V. (NASDAQ:IMTX) with a Buy rating and announced a price target of $10, with the firm’s analysis suggesting a promising outlook for the company considering its approach to treating 2L+ Cutaneous Melanoma, especially with the IMA203.

While we acknowledge the risk and potential of IMTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IMTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy and 13 Best Big Name Stocks to Buy Now.

Disclosure: None.